Price history
Select outcomes to plot.
Description
Eli Lilly licenses Peptron’s SmartDepot by October 7? is a binary outcome market assessing whether a binding commercial license or technology transfer agreement granting Eli Lilly direct commercial rights to Peptron’s SmartDepot is signed by 11:59 PM Korea Standard Time. The resolution hinges on an official filing or announcement from Eli Lilly and Peptron, with credible reporting as a fallback if necessary.
Event stats
24h volume
Total volume
Liquidity
Markets
1
Market highlights
Top market
24h gainer
24h loser
Highest volume
Top market
24h gainer
24h loser
Highest volume
Related events
Largest Company end of May?Largest Company end of June?Largest Company end of December 2026?2nd largest company end of May?3rd largest company end of May?IPOs before 2027?Largest IPO by market cap in 2026?Anthropic IPO Closing Market CapWhich companies will be acquired before 2027?Rare Earths Americas IPO Closing Market Cap
Markets
Outcome | Odds | Spread | 24h Change | 24h Volume | Total Volume | Liquidity | |
|---|---|---|---|---|---|---|---|
| Eli Lilly licenses Peptron’s SmartDepot by October 7? | — | — | — | — | — | — |
Rules
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.